Hamostaseologie 2022; 42(04): 221-228
DOI: 10.1055/a-1646-3392
Review Article

Platelet Dysregulation in the Pathobiology of COVID-19

Rebecca A. Mellema
1   Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, United States
,
Jacob Crandell
2   Molecular Medicine Program, University of Utah, Salt Lake City, Utah, United States
,
Aaron C. Petrey
1   Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, United States
2   Molecular Medicine Program, University of Utah, Salt Lake City, Utah, United States
› Author Affiliations
Funding U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. R00HL135265.

Abstract

Coronavirus disease 2019 (COVID-19) encompasses a broad spectrum of clinical manifestations caused by infection with severe acute respiratory syndrome coronavirus 2.

Patients with severe disease present with hyperinflammation which can affect multiple organs which often include observations of microvascular and macrovascular thrombi. COVID-19 is increasingly recognized as a thromboinflammatory disease where alterations of both coagulation and platelets are closely linked to mortality and clinical outcomes. Although platelets are most well known as central mediators of hemostasis, they possess chemotactic molecules, cytokines, and adhesion molecules that are now appreciated as playing an important role in the regulation of immune response. This review summarizes the current knowledge of platelet alterations observed in the context of COVID-19 and their impact upon disease pathobiology.



Publication History

Received: 14 May 2021

Accepted: 20 September 2021

Article published online:
08 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany